Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
medline:
29
5
2023
pubmed:
6
4
2023
entrez:
5
4
2023
Statut:
ppublish
Résumé
Consensus molecular subtypes (CMSs) were evaluated as prognostic and predictive biomarkers of patients with CMSs were determined in the safety set (ie, patients that received induction) and full analysis set (FAS; ie, randomly assigned patients who received maintenance) and correlated with median progression-free survival (PFS) and overall survival (OS) since the start of induction or maintenance treatment and objective response rates (ORRs). Hazard ratios (HRs) and 95% CI were calculated by univariate/multivariate Cox regression analyses. Of 377 patients of the safety set, 296 (78.5%) had available CMS data: CMS1/2/3/4: 29 (9.8%)/122 (41.2%)/33 (11.2%)/112 (37.8%) and unclassifiable: 17 (5.7%). The CMSs were prognostic biomarkers in terms of PFS ( The CMS had a prognostic impact on PFS, OS, and ORR in
Identifiants
pubmed: 37018649
doi: 10.1200/JCO.22.02582
doi:
Substances chimiques
Panitumumab
6A901E312A
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT01991873']
Types de publication
Clinical Trial, Phase II
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM